1. Startseite
  2. Aktien
  3. Vereinigtes Königreich
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Andere Sprachen
    AZN   GB0009895292


Verzögert London Stock Exchange  -  17:39 01.07.2022
10722.00 GBX   -0.72%
01.07.SEKTOR-UPDATE : Aktien des Gesundheitswesens erholen sich spät
01.07.SEKTOR-UPDATE : Aktien aus dem Gesundheitssektor suchen nach Orientierung
01.07.AstraZeneca erreicht primäre Endpunkte in Studien zu Leber- und Gallengangskrebs im Spätstadium
ÜbersichtAlle NewsAnalystenempfehlungenAndere SprachenPressemitteilungenOffizielle PublikationenBranchen-NewsMarketScreener Analysen
Nachrichten in anderen Sprachen über ASTRAZENECA PLC
01.07.SECTOR UPDATE : Health Care Stocks Rebound Late
01.07.SECTOR UPDATE : Health Care Stocks Struggling for Direction
01.07.AstraZeneca Meets Primary Endpoints in Late-Stage Liver, Biliary Tract Cancers Trials
01.07.AstraZeneca Shares Data at EASL and ESMO World GI for IMFINZI® (durvalumab) Combination..
01.07.AstraZeneca Enters New 3-Year Agreement with Oxford Biomedica
01.07.New chronic kidney disease (CKD) study indicates that CKD is present in one out of ten ..
01.07.Imfinzi plus chemotherapy significantly improved pathologic complete response in AEGEAN..
01.07.Pharmaceutical companies still have the upper hand
01.07.Oxford BioMedica Extends Agreement With AstraZeneca for Covid-19 Vaccine Facility
01.07.Oxford Biomedica signs new deal to make AstraZeneca COVID shot
01.07.Oxford Biomedica, AstraZeneca Unit Ink Three-year Deal To Manufacture COVID-19 Vaccines
01.07.Oxford Biomedica signs new deal to make AstraZeneca COVID shot
30.06.COVID SCIENCE-Pausing methotrexate improves booster response; first-trimester of pregna..
30.06.IMFINZI® (durvalumab) Plus Chemotherapy Significantly Improved Pathologic Complete Resp..
30.06.AstraZeneca Says Phase 3 Trial Interim Data Show Imfinzi Plus Chemotherapy Improves Pat..
30.06.ASTRAZENECA : Imfinzi plus chemotherapy significantly improved pathologic complete respons..
30.06.Astrazeneca's Imfinzi Plus Chemotherapy Significantly Improves Pathologic Complete Resp..
30.06.ASTRAZENECA : Imfinzi prometteur dans le cancer du poumon
30.06.S.Korea authorises AstraZeneca COVID therapy Evusheld for vulnerable people
30.06.AstraZeneca says Imfinzi combo shows promise in late-stage lung cancer trial
30.06.AstraZeneca's Late-stage Lung Cancer Drug Trial Shows Improved Pathologic Complete Resp..
30.06.AstraZeneca Announces Positive High-Level Results from A Planned Interim Analysis of th..
30.06.AstraZeneca Says Imfinzi Improved Pathologic Complete Response in Lung Cancer
29.06.European ADRs Move Slightly Higher in Wednesday Trading
29.06.FTSE 100 Closes Down 0.2% as Uncertainty Persists
29.06.FTSE 100 retreats from two-week high on slowdown worries
29.06.Taiwan to receive first doses of Novavax COVID vaccine this week
29.06.SK Bioscience Shares Advance on Covid-19 Vaccine Approval
28.06.AstraZeneca and Merck - LYNPARZA (olaparib) Receives Positive Opinion From EU CHMP as A..
28.06.Amref and AstraZeneca launch mobile clinics to support last mile COVID-19 vaccination e..
28.06.Amref and AstraZeneca launch mobile clinics to support last mile COVID-19 vaccination e..
27.06.ASTRAZENECA : l'Enhertu recommandé par le CMUH
27.06.European Union Recommends Approval for AstraZeneca and Daiichi Sankyo's Enhertu
27.06.Merck, AstraZeneca's Lynparza Obtains EMA's Committee Recommendation as Adjuvant Treatm..
27.06.Enhertu recommended for approval in the EU by CHMP for patients with HER2-positive meta..
27.06.AstraZeneca Pharma India Sets Record Date for Fiscal 2022 Final Dividend
27.06.SOUTHWEST ÉCONOMISE, RWE MENACE, ZAL : Planète Bourse du lundi 27 juin
27.06.AstraZeneca Partner Daiichi Sankyo Says EMA's Committee Backs Approval of Trastuzumab D..
27.06.ASTRAZENECA : avis favorable du CHMP pour Enhertu
27.06.AstraZeneca's Lynparza, Enhertu Win EU Panel's Backing for Approval in Breast Cancer
27.06.AstraZeneca PLC Announces Lynparzar Ecommended for Approval in the EU by CHMP as Adjuva..
27.06.Trastuzumab Deruxtecan Recommends for Approval in the EU by CHMP for Patients with HER2..
27.06.AstraZeneca-Daiichi Sankyo Enhertu Breast Cancer Drug Is Recommended for EU Approval
27.06.AstraZeneca Lynparza Breast Cancer Treatment Is Recommended for EU Approval
24.06.AstraZeneca-Merck & Co's Lynparza Receives EU Panel's Positive Opinion for New Indicati..
24.06.ASTRAZENECA : un nouvel avis positif du CHMP pour le Lynparza
24.06.Sanofi, GSK variant-specific COVID shot found effective against Omicron
23.06.COVID/VALNEVA : un comité de l'EMA recommande l'autorisation de son vaccin
23.06.AstraZeneca Says Health Canada Expands Approved of Breast Cancer Treatment Enhertu
23.06.EU watchdog backs Valneva's COVID shot as contract talks go on
23.06.ASTRAZENECA : résultats positifs dans la maladie de Wilson
23.06.AstraZeneca Drug Candidate to Treat Wilson Disease Meets Primary Endpoint in Phase 3 Tr..
23.06.AstraZeneca's Investigational Drug Meets Primary Endpoint for Wilson Disease
23.06.ALXN1840 Shows Rapid and Sustained Improvement in Copper Mobilization From Tissues, Pot..
23.06.ASTRAZENECA : ALXN1840 shows rapid and sustained improvement in copper mobilisation from t..
22.06.ADRs End Lower; ArcelorMittal, AstraZeneca Trade Actively
22.06.European Medicines Agency Validates AstraZeneca-Daiichi Sankyo Application for Breast C..
22.06.AstraZeneca and Merck - Results From Phase 3 PROpel Trial of LYNPARZA (olaparib) Plus A..
22.06.PROpel Phase III trial positive results of LYNPARZA (olaparib) plus abiraterone in 1st-..
22.06.ASTRAZENECA : l'EMA accepte un dossier dans le cancer du sein
22.06.Improved outcome for prostate cancer patients in Phase III PROpel trial
22.06.AstraZeneca Partner Daiichi Sankyo Says Type II Variation Application for Breast Cancer..
22.06.COVID-19 vaccine scheme for world's poorest pushes for delivery slowdown
22.06.Rode start in Brussel verwacht
22.06.Biocartis, AstraZeneca To Jointly Develop Companion Lung Cancer Diagnostic Test For Tag..
22.06.Biocartis en AstraZeneca breiden samenwerking uit
22.06.Biocartis Group NV Announces New Agreement with AstraZeneca for the Development and Mar..
22.06.AstraZeneca-Merck & Co.'s Lynparza Delays Prostate Cancer Progression In Late-stage Stu..
21.06.Merck, AstraZeneca Publish Phase 3 Data for Lynparza-Abiraterone Combo to Treat Prostat..
21.06.European Bourses Close in Green for Second Consecutive Day
21.06.ASTRAZENECA : de bons résultats dans le cancer de la prostate
21.06.Ionis Pharmaceuticals, AstraZeneca's Eplontersen Meets Primary, Secondary Endpoints in ..
21.06.PROpel Phase III Trial Positive Results of LYNPARZA® (olaparib) Plus Abiraterone in 1st..
21.06.Eplontersen Met Co-Primary and Secondary Endpoints in Interim Analysis of the NEURO-TTR..
21.06.ASTRAZENECA : résultats encourageants pour l'eplontersen
1  2  3  4  5  6  7  8  9  10Weiter